nivolumab,ipilimumab
bms
['lcsm,(-blcsm)', ' ipi ', 'nivo']
5y os cm227z 5 y landmark for nivo ipi was 24% in pdl1&gt;1% and 19% in pdl1 &lt;1%. great outcomes in 5y survivors. i like consistency. i don t like non-reimbursed status in uk #asco22 #lcsm 
Consultant Medical Oncologist, UK. Views are hypothesis generating discourse. Post COVID dabbling in garden.